Trials / Completed
CompletedNCT00228969
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- SK Life Science, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RWJ-333369 |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2005-09-29
- Last updated
- 2012-08-02
Locations
61 sites across 8 countries: United States, Argentina, Hungary, Netherlands, Poland, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00228969. Inclusion in this directory is not an endorsement.